Immunoglobulin G spike receptor binding domain antibody levels similar after primary series, booster dose<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Dec. 30, 2022 (HealthDay News) — COVID-19 mRNA vaccine boosters increase antibody duration, but do not increase antibody levels, according to a study recently published in the Annals of Allergy, Asthma & Immunology<\/em>.<\/em><\/p>\n Samuel M. Ailsworth, from the University of Virginia in Charlottesville, and colleagues examined the magnitude and durability of spike receptor-binding domain (S-RBD) immunoglobulin (Ig)G after booster mRNA COVID-19 vaccination versus the primary series. In addition, S-RBD IgG levels were compared after BNT162b2 and mRNA-1273 boosters. Adults in an employee-based cohort provided serum and completed questionnaires, including information about previous COVID-19 infection; 228 adults had samples collected between seven and 150 days after the primary series and 117 had samples collected in the same time frame after the booster dose.<\/p>\n The researchers found that antibody levels were similar from seven to 31 days after the primary series and booster; however, regardless of prior infection status, S-RBD IgG was more durable over time after the booster. Up to five months, mRNA-1273 postboost antibody levels exceeded those of BNT162b2.<\/p>\n “Our initial thought was that boosters would lead to higher antibody levels than the primary vaccine series, but that was not what we found,” Ailsworth said in a statement. “Instead, we found that the booster led to longer lasting antibodies.”<\/p>\n